Bank of New York Mellon Corp Grows Position in Bruker Co. (NASDAQ:BRKR)

Bank of New York Mellon Corp raised its position in Bruker Co. (NASDAQ:BRKR) by 7.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 988,863 shares of the medical research company’s stock after purchasing an additional 69,806 shares during the quarter. Bank of New York Mellon Corp owned 0.65% of Bruker worth $57,967,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. FMR LLC grew its stake in shares of Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after buying an additional 2,521,904 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its stake in shares of Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after buying an additional 666,617 shares in the last quarter. Point72 DIFC Ltd grew its stake in shares of Bruker by 4,875.9% in the third quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company’s stock valued at $32,470,000 after buying an additional 460,722 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Bruker by 1,933.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock valued at $28,331,000 after buying an additional 390,057 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Bruker by 9.6% in the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after buying an additional 318,808 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. TD Cowen lowered their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Barclays lowered their price objective on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Stifel Nicolaus lowered their price objective on Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a research note on Friday, February 14th. Wells Fargo & Company lowered their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Finally, Guggenheim restated a “buy” rating on shares of Bruker in a research note on Monday, February 24th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $70.50.

Bruker Price Performance

Shares of BRKR opened at $46.42 on Wednesday. The firm has a market cap of $7.04 billion, a price-to-earnings ratio of 61.08, a PEG ratio of 2.16 and a beta of 1.16. The stock has a 50 day moving average of $55.83 and a 200-day moving average of $59.49. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. Bruker Co. has a 52 week low of $45.29 and a 52 week high of $94.86.

Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, analysts forecast that Bruker Co. will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Monday, March 17th. Bruker’s dividend payout ratio (DPR) is 26.32%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.